CepTor, Ferring sign letter of intent for superoxide dismutase

By Elaine Rigoli

Tampa, Fla., Sept. 14 - CepTor Corp. has signed a letter of intent with Swiss pharmaceutical group Ferring International Center, SA in which Ferring plans to divest and CepTor plans to purchase recombinant human copper zinc superoxide dismutase (SOD).

Upon completion of due diligence culminating in an agreement with the Food and Drug Administration on the endpoints for a phase 2b clinical trial, CepTor said it will pay Ferring an exclusive option payment.

CepTor may exercise its option for all worldwide rights to SOD with a grant-back royalty-free license to Ferring for infertility indications. Ferring will retain contract manufacturing rights.

SOD is an advanced-stage product with orphan status in the United States and European Union, representing a $400 million market opportunity for an unmet medical need, officials noted.

CepTor is a development-stage biopharmaceutical company based in Hunt Valley, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.